<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051436</url>
  </required_header>
  <id_info>
    <org_study_id>55665</org_study_id>
    <nct_id>NCT05051436</nct_id>
  </id_info>
  <brief_title>The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics</brief_title>
  <official_title>The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Kern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator hypothesizes that treatment with the ÃŸ3 agonist mirabegron results in&#xD;
      improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant&#xD;
      human research participants, and this is further improved by combination therapy with&#xD;
      tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic&#xD;
      patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants will complete a standard oral glucose tolerance test using 75 g of glucose at baseline and blood glucose will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>14 weeks</time_frame>
    <description>Participants will complete a standard oral glucose tolerance test using 75 g of glucose at 14 weeks and blood glucose will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant hemoglobin A1C will be evaluated at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>14 weeks</time_frame>
    <description>Participant hemoglobin A1C will be evaluated at 14 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fat biopsy</measure>
    <time_frame>Baseline</time_frame>
    <description>Beiging of fat as measured in the lab by histochemistry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fat biopsy</measure>
    <time_frame>14 weeks</time_frame>
    <description>Beiging of fat as measured in the lab by histochemistry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle biopsy</measure>
    <time_frame>Baseline</time_frame>
    <description>Fiber type, as measured in the lab by histochemistry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Muscle biopsy</measure>
    <time_frame>14 weeks</time_frame>
    <description>Fiber type, as measured in the lab by histochemistry.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Pre-diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Mirabegron (M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered for 12 weeks after baseline procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil (T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered for 12 weeks after baseline procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirabegron and Tadalafil (MT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both drugs will be administered for 12 weeks after baseline procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (P)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron 50 MG</intervention_name>
    <description>Mirabegron 50 mg/day will be administered for 14 weeks.</description>
    <arm_group_label>Mirabegron (M)</arm_group_label>
    <arm_group_label>Mirabegron and Tadalafil (MT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 10 MG</intervention_name>
    <description>Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.</description>
    <arm_group_label>Mirabegron and Tadalafil (MT)</arm_group_label>
    <arm_group_label>Tadalafil (T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered for 14 weeks after baseline procedures.</description>
    <arm_group_label>Placebo (P)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin A1C between 5.7 and 6.4&#xD;
&#xD;
          -  Body mass index between 27 and 45&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Chronic use of any antidiabetic medications&#xD;
&#xD;
          -  Any unstable medical condition&#xD;
&#xD;
          -  Use of steroids or daily use of NSAIDS&#xD;
&#xD;
          -  History of chronic inflammatory conditions&#xD;
&#xD;
          -  Use of anticoagulants&#xD;
&#xD;
          -  Contraindications to the use of mirabegron or tadalafil&#xD;
&#xD;
          -  Any condition deemed risky by the study physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Kern, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Douglas Long, M.S.</last_name>
    <phone>859-323-5438</phone>
    <email>delong2@uky.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philip Kern, M.D.</last_name>
    <phone>859-218-1394</phone>
    <email>pake222@uky.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Douglas Long</last_name>
      <phone>859-323-5438</phone>
      <email>delong2@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Kern, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Philip Kern</investigator_full_name>
    <investigator_title>M.D</investigator_title>
  </responsible_party>
  <keyword>Tadalafil</keyword>
  <keyword>Mirabegron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

